


1324

1325 Supporting Information



1326

1327 **Fig S1 Evaluation sgRNA strength and log concentration as predictors of CRISPRi-DR model**

1328 **through comparison of distribution of r^2 values of full (CRISPRi-DR) and ablated (M_s and M_d)**

1329 **models for each gene in each experiment.**


1330 The horizontal line is where $r^2 = 0.5$. The average r^2 M_s model for all genes across all the

1331 experiments is 0.42, the average r^2 for the M_d model is 0.07. This alongside the Log-likelihood

1332 tests indicate sgRNA strength is the more significant predictor. However, the full CRISPRi-DR

1333 model outperforms both M_d and M_s (average r^2 is 0.50) indicating the inclusion of both sgRNA
1334 strength and log concentration is needed for accurate assessment of significant sgRNA depletion
1335 in a gene in a condition.

1336



1337

1338 **Fig S2 Distribution of average CV of sgRNAs in significant genes (depleted and enriched) in the**
1339 **CRISPRi-DR model and MAGECK.**

1340 In this Fig, we see all the noise distributions for hits in MAGECK and the CRISPRi-DR model for
1341 all experiments. The dashed panel is that of RIF D10. The same distribution of noise of hits can
1342 be seen in Fig 5. The trend seen with RIF D10 is present with all the experiments except LEVO
1343 D10. We see that the CRISPRi-DR model is unimodal with a low CV as the mode, whereas
1344 MAGECK shows significant genes with low average CV values but also a significant amount of
1345 genes with high average CV values. LEVO D10 was left out of this plot due to the low number of
1346 hits in either model.

1347

1348 **Table S1. Ranking of Select Genes using the CRISPRi-DR model in 1 Day, 5 day and 10 Day pre-**
1349 **depletion of treated libraries.**

1350 An extended version of Table 2, where the CRISPRi-DR model is run on each gene for each drug
1351 and pre-depletion day. The coefficient for the slope of concentration dependence (β_c) is
1352 extracted from the fitted regressions and used to rank the genes in both increasing order (for
1353 depletion) and inversely (for enrichment). Green reflects results consistent with expectations
1354 based on knowledge of known gene-drug interactions.

1355

1356 **Table S2. Comparison of significant interactions Identified by CRISPR analysis methods of**
1357 **EMB, INH, LEVO, VAN and RIF CRISPRi screens**

1358 For each drug and pre-depletion day of the selected datasets, all 7 CRISPR methods were run.
1359 For methods that do not account for multiple concentrations, they were run separately for each
1360 concentration and the overall significant interactions are also addressed post-combination of
1361 the individual runs using Fisher's method. The comparison of the significant interactions
1362 identified by the models was evaluated using an objectively defined list of true positives. The
1363 genes identified by Xu, DeJesus (35) were used as the "ground truth" against which the other
1364 model's results were compared. For LEVO, genes in the DNA Damaging pathway are used.
1365 Recall, Precision and F1-score columns are colored such that higher values are more green.

1366

1367 **Table S3. Matrices for comparison of significant interactions Identified by CRISPRi-DR and**
1368 **MAGeCK for each drug and pre-depletion day.**

1369 The table presents the results of CRISPRi-DR and MAGeCK analyses for different drugs and pre-
1370 depletion days. Significant interactions are compared in matrix form. Cells with red font indicate
1371 low overlaps between the interactions found by the two models, while cells with green font
1372 represent high overlaps.

1373

1374 **Supplemental File S1**

1375 We expand on the following four topics from the main text in this document: 1) An assessment
1376 of CRISPRi-DR, MAGeCK and MAGeCK-MLE on datasets with simulated noise, 2) Comparison of
1377 CRISPRi-DR to other analysis methods using CGI datasets, 3) Analysis of *E. coli* CRISPRi screens
1378 using CRISPRi-DR and, 4) The minimum number of sgRNAs recommended per gene in CRISPRi-
1379 DR.

1380